Company intelligence / Profile preview

Harbin Yirui Pharmaceutical

Hangzhou, Zhejiang, Chinapmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Commercial

Overview

Yirui Pharma has successfully completed a U.S. Phase I clinical trial for its lead candidate, YR001, a topical Kv1.3 inhibitor for autoimmune skin diseases such as atopic dermatitis and psoriasis, demonstrating favorable safety and tolerability. The oral formulation of this compound targets inflammatory bowel disease and alopecia, with plans for NDA submissions between 2026–2028. Additional pipeline assets are in preclinical or IND stages targeting diabetic complications, retinal disease, pruritus, and erectile dysfunction.

Therapeutic areas: Men's HealthDermatologyGastroenterologyOphthalmologyNephrology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Harbin Yirui Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Harbin Yirui Pharmaceutical.

Explore the full profile